| P50 | author | Henrik Enghusen Poulsen | Q33310622 |
| | Filip K Knop | Q59659637 |
| | Tina Vilsbøll | Q60393741 |
| P2093 | author name string | Jørgen Rungby | |
| | Emil List Larsen | |
| | Vanja Cejvanovic | |
| | Laura Kofoed Kjær | |
| P2860 | cites work | SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? | Q26750510 |
| | Clinical Relevance of Biomarkers of Oxidative Stress | Q26785512 |
| | Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): a paradigm worth exploring | Q26861082 |
| | Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 |
| | Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 |
| | SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials | Q28710019 |
| | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 |
| | Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q34457919 |
| | The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity | Q34524690 |
| | Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes | Q34670462 |
| | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 |
| | Intensive glucose control and macrovascular outcomes in type 2 diabetes. | Q34995674 |
| | Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people | Q35004093 |
| | Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy | Q35043750 |
| | Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study | Q35117192 |
| | Urinary markers of nucleic acid oxidation and long-term mortality of newly diagnosed type 2 diabetic patients | Q35563607 |
| | The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes | Q35903101 |
| | Association between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes: a population-based cohort study. | Q36629664 |
| | Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. | Q36750672 |
| | SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study | Q36820604 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a biomarker in type 2 diabetes | Q37912415 |
| | RNA modifications by oxidation: a novel disease mechanism? | Q37981450 |
| | SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. | Q37981884 |
| | Assays for urinary biomarkers of oxidatively damaged nucleic acids | Q37986872 |
| | SPIRIT 2013 statement: defining standard protocol items for clinical trials | Q38072250 |
| | Detection and interpretation of 8-oxodG and 8-oxoGua in urine, plasma and cerebrospinal fluid | Q38116269 |
| | Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension | Q38710995 |
| | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 |
| | Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index | Q41104925 |
| | Simvastatin and oxidative stress in humans: A randomized, double-blinded, placebo-controlled clinical trial | Q42725614 |
| | Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study | Q43181601 |
| | Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis | Q43290649 |
| | Determination of malondialdehyde as dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: comparison with ultraviolet-visible spectrophotometry | Q43714076 |
| | Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials | Q46420088 |
| | Oltipraz chemoprevention trial in Qidong, People's Republic of China: Unaltered oxidative biomarkers | Q61794754 |
| P433 | issue | 5 | |
| P921 | main subject | placebo | Q269829 |
| | type 2 diabetes | Q3025883 |
| | empagliflozin | Q5373824 |
| P304 | page(s) | e014728 | |
| P577 | publication date | 2017-05-09 | |
| P1433 | published in | BMJ Open | Q17003470 |
| P1476 | title | The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial | |
| P478 | volume | 7 | |